Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Giant Cell Tumor of Tendon Sheath 6Synovitis, Pigmented Villonodular 3Melanoma 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Solid Tumor 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Paclitaxel 12atezolizumab 11Gemcitabine 9pembrolizumab 8Injections 6Carboplatin 6Irinotecan 5Docetaxel 5Cetuximab 5tocilizumab 4navitoclax 4Leucovorin 4Fluorouracil 4Bevacizumab 4olaparib 3cobimetinib 3Oxaliplatin 3Nivolumab 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2tivozanib 2tislelizumab 2spartalizumab 2ridaforolimus 2plocabulin 2obinutuzumab 2motesanib diphosphate 2liposomal doxorubicin 2linifanib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumors × pexidartinib × Clear all
NCT01525602 2020-07-16

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

Daiichi Sankyo

Phase 1 Completed
74 enrolled 22 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡